Completed PHASE4 INTERVENTIONAL 1-arm NCT04676373

Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen (APOLLO-LOPD)

A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatment

Sponsor: Genzyme, a Sanofi Company

Conditions Pompe's Disease

Interventions ALGLUCOSIDASE ALFA

Updated 10 times since 2021 Last updated: Feb 6, 2025 Started: Mar 10, 2021 Primary completion: Jul 25, 2024 Completion: Jul 25, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Pompe's Disease and is currently completed. Genzyme, a Sanofi Company leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Mar 2025 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE4
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Oct 2023 — Apr 2024 [monthly]

Recruiting PHASE4

▶ Show 5 earlier versions

Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE4
Nov 2022 — Sep 2023 [monthly]

Recruiting PHASE4
Jun 2022 — Nov 2022 [monthly]

Recruiting PHASE4
Apr 2021 — Jun 2022 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Apr 2021 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• China, China